Changchun BCHT Biotechnology Co.
Clinical trials sponsored by Changchun BCHT Biotechnology Co., explained in plain language.
A Chinese biopharmaceutical company focused on vaccines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a cheaper shingles booster offer same protection? Results expected Sep 2026 (estimated)
- New shingles vaccine trial aims for safer protection in adults 40+ Results expected Dec 2026 (estimated)
- New mRNA vaccine trial aims to stop genital herpes Results expected Mar 2027 (estimated)
-
New vaccine trial aims to shield teens and adults from whooping cough
Vaccine Not yet recruitingThis early-stage trial is testing a new combination vaccine that protects against whooping cough, diphtheria, and tetanus (Tdap) in people aged 10 and older. Researchers want to see if different doses are safe and trigger an immune response. The study involves 96 volunteers and c…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
Experimental flu vaccine with booster enters first human tests
Vaccine Not yet recruitingThis early-stage trial tests a new influenza vaccine that includes a special booster called BK-01 adjuvant. The goal is to see if it is safe and triggers a strong immune response in adults 18 and older. 160 volunteers will receive either the new vaccine, a standard flu vaccine, o…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 08:11 UTC
-
Could a cheaper shingles booster offer same protection?
Prevention Not yet recruitingThis trial tests whether a single dose of a live-attenuated shingles vaccine can effectively boost immunity in adults aged 50 and older who have already received the recombinant shingles vaccine. The study measures antibody and cellular immune responses after the booster. If it w…
Early phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC